Lv2
156 积分 2022-08-19 加入
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
10天前
已完结
Medikamentös induzierte Verlängerung des QT-Intervalls
25天前
已完结
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment
1个月前
已关闭
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
1个月前
已完结
Advances in myopia control strategies for children
1个月前
已关闭
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
2个月前
已完结
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis
2个月前
已关闭
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis
2个月前
已关闭
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
2个月前
已关闭
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
2个月前
已关闭
皖公网安备34019202002308
